Seoul Pharma Co., Ltd (KOSDAQ:018680)

Market Cap	26.12B -34.5%
Revenue (ttm)	51.33B -3.2%
Net Income	725.89M -22.9%
EPS	n/a
Shares Out	11.66M
PE Ratio	35.98
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,084
Open	2,435.00
Previous Close	2,435.00
Day's Range	2,350.00 - 2,460.00
52-Week Range	2,310.00 - 3,810.00
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Seoul Pharma

Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer’ disease; OBCARE to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency; and CH.V, as well as products for schizophrenia, vitamin supplement, obesity, tonic, and m...

• Industry: Pharmaceutical Preparations
• Founded: 1976
• Employees: 172
• Stock Exchange: KOSDAQ
• Ticker Symbol: 018680

Financial Performance

In 2025, Seoul Pharma's revenue was 52.15 billion, a decrease of -2.67% compared to the previous year's 53.58 billion. Earnings were 753.64 million, a decrease of -55.63%.